Species |
Human |
Protein Construction |
TFF3 (Glu22-Phe80) Accession # Q07654 |
|
Purity |
> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC |
Endotoxin Level |
< 1 EU/μg of protein by LAL method |
Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by a chemotaxis bioassay using human MCF-7 cells is less than 10.0 μg/ml, corresponding to a specific activity of > 100.0 IU/mg. |
Expression System |
E. coli |
Theoretical Molecular Weight |
6.6 kDa |
Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
Target Background |
The Trefoil Factor peptides (TFF1, TFF2 and TFF3) are secreted in the gastrointestinal tract, and appear to play an important role in intestinal mucosal defense and repair. TFF-3 is expressed by goblet cells and in the uterus, and has also been shown to express in certain cancers, including colorectal, hepatocellular, and in biliary tumors. TFF3 may be useful as a molecular marker for certain types of cancer, but its role, if any, in tumorigenesis is unknown. TFF3 also promotes airway epithelial cell migration and differentiation. |
Synonyms |
Trefoil Factor 3; TFF-3; ITF; P1B; TFI |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.